Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | TNhYP218 CAR-T cells |
| Synonyms | |
| Therapy Description |
TNhYP218 CAR-T cells are autologous naive and stem cell-like memory (scm) T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting MSLN, which potentially enhance killing of tumor cells expressing MSLN (NCI Thesaurus). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| TNhYP218 CAR-T cells | Autologous anti-mesothelin TNaive/SCM hYP218 CAR T cells | MSLN Immune Cell Therapy 10 | TNhYP218 CAR-T cells are autologous naive and stem cell-like memory (scm) T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting MSLN, which potentially enhance killing of tumor cells expressing MSLN (NCI Thesaurus). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06885697 | Phase I | Cyclophosphamide + Fludarabine TNhYP218 CAR-T cells | Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma | Recruiting | USA | 0 |